Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer

por Uchibori, Ken, Inase, Naohiko, Araki, Mitsugu, Kamada, Mayumi, Sato, Shigeo, Okuno, Yasushi, Fujita, Naoya, Katayama, Ryohei
Publicado 2017

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors

por Ariyasu, Ryo, Kakuto, Sho, Miyadera, Keiki, Akita, Takahiro, Kiritani, Ayu, Tsugitomi, Ryosuke, Amino, Yoshiaki, Uchibori, Ken, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto
Publicado 2023

GSK3 inhibition circumvents and overcomes acquired lorlatinib resistance in ALK-rearranged non-small-cell lung cancer

por Shimizu, Yuki, Okada, Koutaroh, Adachi, Jun, Abe, Yuichi, Narumi, Ryohei, Uchibori, Ken, Yanagitani, Noriko, Koike, Sumie, Takagi, Satoshi, Nishio, Makoto, Fujita, Naoya, Katayama, Ryohei
Publicado 2022

Overcoming resistance by ALK compound mutation (I1171S + G1269A) after sequential treatment of multiple ALK inhibitors in non‐small cell lung cancer

por Takahashi, Ken, Seto, Yosuke, Okada, Koutaroh, Uematsu, Shinya, Uchibori, Ken, Tsukahara, Mika, Oh‐hara, Tomoko, Fujita, Naoya, Yanagitani, Noriko, Nishio, Makoto, Okubo, Kenichi, Katayama, Ryohei
Publicado 2020

Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms

por Yanagitani, Noriko, Uchibori, Ken, Koike, Sumie, Tsukahara, Mika, Kitazono, Satoru, Yoshizawa, Takahiro, Horiike, Atsushi, Ohyanagi, Fumiyoshi, Tambo, Yuichi, Nishikawa, Shingo, Fujita, Naoya, Katayama, Ryohei, Nishio, Makoto
Publicado 2020

Clinical influence of switching companion diagnostic tests for EGFR‐TKs from Therascreen to Cobas v2

por Uchibori, Ken, Takano, Natsuki, Manabe, Ryo, Tsugitomi, Ryosuke, Ogusu, Shinsuke, Tozuka, Takehiro, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Ariyasu, Ryo, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto
Publicado 2021

Characteristics of central nervous system progression in non‐small cell lung cancer treated with crizotinib or alectinib

por Sakamoto, Hiroaki, Yanagitani, Noriko, Manabe, Ryo, Tsugitomi, Ryosuke, Ogusu, Shinsuke, Tozuka, Takehiro, Yoshida, Hiroshi, Amino, Yoshiaki, Ariyasu, Ryo, Uchibori, Ken, Kitazono, Satoru, Tasaka, Sadatomo, Nishio, Makoto
Publicado 2021

Clinical characteristics of patients with KRAS mutation detected by liquid biopsy

por Amino, Yoshiaki, Low, Siew‐Kee, Ninomiya, Hironori, Kiritani, Ayu, Miyadera, Keiki, Kakuto, Sho, Akita, Takahiro, Tsugitomi, Ryosuke, Ariyasu, Ryo, Uchibori, Ken, Kitazono, Satoru, Yanagitani, Noriko, Nishio, Makoto
Publicado 2023

Barcode sequencing identifies resistant mechanisms to epidermal growth factor receptor inhibitors in circulating tumor DNA of lung cancer patients

por Kitazono, Satoru, Sakai, Kazuko, Yanagitani, Noriko, Ariyasu, Ryo, Yoshizawa, Takahiro, Dotsu, Yosuke, Koyama, Junji, Saiki, Masafumi, Sonoda, Tomoaki, Nishikawa, Shingo, Uchibori, Ken, Horiike, Atsushi, Nishio, Kazuto, Nishio, Makoto
Publicado 2019

Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice

por Ariyasu, Ryo, Uchibori, Ken, Ninomiya, Hironori, Ogusu, Shinsuke, Tsugitomi, Ryosuke, Manabe, Ryo, Sakamaoto, Hiroaki, Tozuka, Takehiro, Yoshida, Hiroshi, Amino, Yoshiaki, Kitazono, Satoru, Yanagitani, Noriko, Takeuchi, Kengo, Nishio, Makoto
Publicado 2020

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand...

por Tozuka, Takehiro, Kitazono, Satoru, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Uematsu, Shinya, Yoshizawa, Takahiro, Hasegawa, Tsukasa, Uchibori, Ken, Yanagitani, Noriko, Horiike, Atsushi, Horai, Takeshi, Seike, Masahiro, Gemma, Akihiko, Nishio, Makoto
Publicado 2020

Poor efficacy of anti‐programmed cell death‐1/ligand 1 monotherapy for non‐small cell lung cancer patients with active brain metastases

por Tozuka, Takehiro, Kitazono, Satoru, Sakamoto, Hiroaki, Yoshida, Hiroshi, Amino, Yoshiaki, Uematsu, Shinya, Yoshizawa, Takahiro, Hasegawa, Tsukasa, Ariyasu, Ryo, Uchibori, Ken, Yanagitani, Noriko, Horai, Takeshi, Seike, Masahiro, Gemma, Akihiko, Nishio, Makoto
Publicado 2020

Monitoring epidermal growth factor receptor C797S mutation in Japanese non–small cell lung cancer patients with serial cell‐free DNA evaluation using digital droplet PCR

por Ariyasu, Ryo, Uchibori, Ken, Sasaki, Takaaki, Tsukahara, Mika, Kiyotani, Kazuma, Yoshida, Ryohei, Ono, Yusuke, Kitazono, Satoru, Ninomiya, Hironori, Ishikawa, Yuichi, Mizukami, Yusuke, Yanagitani, Noriko, Fujita, Naoya, Nishio, Makoto, Katayama, Ryohei
Publicado 2021

Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with Genexus™ integrated sequencer

por Low, Siew-Kee, Ariyasu, Ryo, Uchibori, Ken, Hayashi, Rie, Chan, Hiu Ting, Chin, Yoon Ming, Akita, Takahiro, Harutani, Yuhei, Kiritani, Ayu, Tsugitomi, Ryosuke, Manabe, Ryo, Ogusu, Shinsuke, Amino, Yoshiaki, Kitazono, Satoru, Yanagitani, Noriko, Nakamura, Yusuke, Nishio, Makoto
Publicado 2022

Soluble PD-L1 works as a decoy in lung cancer immunotherapy via alternative polyadenylation

por Sagawa, Ray, Sakata, Seiji, Gong, Bo, Seto, Yosuke, Takemoto, Ai, Takagi, Satoshi, Ninomiya, Hironori, Yanagitani, Noriko, Nakao, Masayuki, Mun, Mingyon, Uchibori, Ken, Nishio, Makoto, Miyazaki, Yasunari, Shiraishi, Yuichi, Ogawa, Seishi, Kataoka, Keisuke, Fujita, Naoya, Takeuchi, Kengo, Katayama, Ryohei
Publicado 2022

A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)

por Sakashita, Hiroyuki, Uchibori, Ken, Jin, Yasuto, Tsutsui, Toshiharu, Honda, Takayuki, Sakakibara, Rie, Mitsumura, Takahiro, Nukui, Yoshihisa, Shirai, Tsuyoshi, Masuo, Masahiro, Suhara, Kozo, Furusawa, Haruhiko, Yamashita, Takaaki, Ohba, Takehiko, Saito, Kazuhito, Takagiwa, Jun, Miyashita, Yoshihiro, Inase, Naohiko, Miyazaki, Yasunari
Publicado 2022

Microsecond-timescale MD simulation of EGFR minor mutation predicts the structural flexibility of EGFR kinase core that reflects EGFR inhibitor sensitivity

por Yoshizawa, Takahiro, Uchibori, Ken, Araki, Mitsugu, Matsumoto, Shigeyuki, Ma, Biao, Kanada, Ryo, Seto, Yosuke, Oh-hara, Tomoko, Koike, Sumie, Ariyasu, Ryo, Kitazono, Satoru, Ninomiya, Hironori, Takeuchi, Kengo, Yanagitani, Noriko, Takagi, Satoshi, Kishi, Kazuma, Fujita, Naoya, Okuno, Yasushi, Nishio, Makoto, Katayama, Ryohei
Publicado 2021